Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

198 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pre-existing inflammatory disease predicts cutaneous immunotherapy toxicity development: A multi-institutional cohort study.
Wan G, Nguyen N, Leung BW, Rashdan H, Tang K, Roster K, Collier MR, Ugwu-Dike PO, Raval NS, Alexander NA, Jairath R, Phillipps J, Amadife M, Zhang S, Gusev A, Chen ST, Reynolds KL, LeBoeuf NR, Kwatra SG, Semenov YR. Wan G, et al. Among authors: reynolds kl. J Am Acad Dermatol. 2024 Feb;90(2):418-420. doi: 10.1016/j.jaad.2023.09.082. Epub 2023 Oct 13. J Am Acad Dermatol. 2024. PMID: 37838257 No abstract available.
Impact of COVID-19 on Patients with Cancer Receiving Immune Checkpoint Inhibitors.
Bui AN, Tyan K, Giobbie-Hurder A, Klein IA, Manos MP, Zubiri L, Reynolds K, Grover S, Weinhouse GL, Ott PA, LeBoeuf NR, Rahma O. Bui AN, et al. J Immunother Precis Oncol. 2021 May 14;4(2):35-44. doi: 10.36401/JIPO-20-34. eCollection 2021 May. J Immunother Precis Oncol. 2021. PMID: 35663537 Free PMC article.
Germline variants associated with toxicity to immune checkpoint blockade.
Groha S, Alaiwi SA, Xu W, Naranbhai V, Nassar AH, Bakouny Z, El Zarif T, Saliby RM, Wan G, Rajeh A, Adib E, Nuzzo PV, Schmidt AL, Labaki C, Ricciuti B, Alessi JV, Braun DA, Shukla SA, Keenan TE, Van Allen E, Awad MM, Manos M, Rahma O, Zubiri L, Villani AC, Fairfax B, Hammer C, Khan Z, Reynolds K, Semenov Y, Schrag D, Kehl KL, Freedman ML, Choueiri TK, Gusev A. Groha S, et al. Among authors: reynolds k. Nat Med. 2022 Dec;28(12):2584-2591. doi: 10.1038/s41591-022-02094-6. Epub 2022 Dec 16. Nat Med. 2022. PMID: 36526723 Free PMC article.
Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: A multi-institutional cohort study.
Zhang S, Tang K, Wan G, Nguyen N, Lu C, Ugwu-Dike P, Raval N, Seo J, Alexander NA, Jairath R, Phillipps J, Leung BW, Roster K, Chen W, Zubiri L, Boland G, Chen ST, Tsao H, Demehri S, LeBoeuf NR, Reynolds KL, Yu KH, Gusev A, Kwatra SG, Semenov YR. Zhang S, et al. Among authors: reynolds kl. J Am Acad Dermatol. 2023 May;88(5):1024-1032. doi: 10.1016/j.jaad.2022.12.048. Epub 2023 Feb 2. J Am Acad Dermatol. 2023. PMID: 36736626 Free PMC article.
Tumor-infiltrating lymphocytes as a predictive biomarker of cutaneous immune-related adverse events after immune checkpoint blockade in patients with advanced melanoma.
Stephens MR, Asdourian MS, Jacoby TV, Shah N, Thompson LL, Otto T, Semenov YR, Reynolds KL, Sullivan RJ, Foreman RK, Chen ST. Stephens MR, et al. Among authors: reynolds kl. J Am Acad Dermatol. 2023 Jul;89(1):140-142. doi: 10.1016/j.jaad.2023.01.040. Epub 2023 Feb 15. J Am Acad Dermatol. 2023. PMID: 36806644 Free PMC article. No abstract available.
Influence of melanoma type on incidence and downstream implications of cutaneous immune-related adverse events in the setting of immune checkpoint inhibitor therapy.
Nguyen N, Wan G, Ugwu-Dike P, Alexander NA, Raval N, Zhang S, Jairath R, Phillipps J, Leung B, Roster K, Seo J, Lu C, Tang K, Choi MS, DeSimone MS, Theodosakis N, Amadife M, Cox N, Le TK, Liu F, Chen W, Bai X, Boland G, Liu D, Hurlbert MS, LeBoeuf N, Reynolds KL, Yu KH, Tsao H, Asgari M, Gusev A, Kwatra SG, Semenov YR. Nguyen N, et al. Among authors: reynolds kl. J Am Acad Dermatol. 2023 Jun;88(6):1308-1316. doi: 10.1016/j.jaad.2023.02.014. Epub 2023 Feb 22. J Am Acad Dermatol. 2023. PMID: 36828138 Free PMC article.
Associations between dermatologic immune-related adverse event morphologies and systemic immunomodulatory/immunosuppressive treatment: A large retrospective cohort study.
Reardon RM, Perlman KL, Asdourian MS, Shah N, Jacoby TV, Thompson LL, Reynolds KL, Semenov YR, Chen ST. Reardon RM, et al. Among authors: reynolds kl. J Am Acad Dermatol. 2024 Jun;90(6):1268-1271. doi: 10.1016/j.jaad.2024.01.070. Epub 2024 Feb 9. J Am Acad Dermatol. 2024. PMID: 38341147 No abstract available.
Cancer type and histology influence cutaneous immunotherapy toxicities: a multi-institutional cohort study.
Wan G, Khattab S, Leung BW, Zhang S, Nguyen N, Tran M, Lin C, Chang C, Alexander N, Jairath R, Phillipps J, Tang K, Rajeh A, Zubiri L, Chen ST, Demehri S, Yu KH, Gusev A, Kwatra SG, LeBoeuf NR, Reynolds KL, Semenov YR. Wan G, et al. Among authors: reynolds kl. Br J Dermatol. 2024 Jun 20;191(1):117-124. doi: 10.1093/bjd/ljae053. Br J Dermatol. 2024. PMID: 38366637 Free PMC article.
Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort study.
Wan G, Chen W, Khattab S, Roster K, Nguyen N, Yan B, Rajeh A, Seo J, Rashdan H, Zubiri L, Hadfield MJ, Demehri S, Yu KH, Lotter W, Gusev A, LeBoeuf NR, Reynolds KL, Kwatra SG, Semenov YR. Wan G, et al. Among authors: reynolds kl. Lancet Oncol. 2024 Aug;25(8):1053-1069. doi: 10.1016/S1470-2045(24)00278-X. Epub 2024 Jul 15. Lancet Oncol. 2024. PMID: 39025103
198 results